{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:01:04Z","timestamp":1787022064165,"version":"build-2736575974"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0234909","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T14:13:32Z","timestamp":1592921612000},"page":"e0234909","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout"],"prefix":"10.1371","volume":"15","author":[{"given":"Fu-Shun","family":"Yen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Lun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8209-9627","authenticated-orcid":true,"given":"Chii-Min","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"key":"pone.0234909.ref001","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.7326\/0003-4819-34-6-1421","article-title":"Serum uric acid in relation to age and physique in health and in coronary heart disease","volume":"34","author":"MM Gertler","year":"1951","journal-title":"Ann Intern Med"},{"key":"pone.0234909.ref002","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1371\/journal.pmed.0020076","article-title":"Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis","volume":"2","author":"JG Wheeler","year":"2005","journal-title":"PLoS Med"},{"key":"pone.0234909.ref003","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/acr.20065","article-title":"Hyperuricemia and coronary heart disease: a systematic review and meta-analysis","volume":"62","author":"SY Kim","year":"2010","journal-title":"Arthritis Care Res"},{"key":"pone.0234909.ref004","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","article-title":"Uric acid and risk of heart failure: a systematic review and meta-analysis","volume":"16","author":"H Huang","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"pone.0234909.ref005","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/art.24612","article-title":"Hyperuricemia and risk of stroke: a systematic review and meta-analysis","volume":"61","author":"SY Kim","year":"2009","journal-title":"Arthritis Rheum"},{"key":"pone.0234909.ref006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7326\/0003-4819-131-1-199907060-00003","article-title":"Serum uric acid and risk for cardiovascular disease and death: the Framingham heart study","volume":"131","author":"BF Culleton","year":"1999","journal-title":"Ann Intern Med"},{"key":"pone.0234909.ref007","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/j.ajkd.2010.01.024","article-title":"Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk","volume":"56","author":"CP Wen","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"pone.0234909.ref008","doi-asserted-by":"crossref","first-page":"F991","DOI":"10.1152\/ajprenal.00283.2001","article-title":"Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism","volume":"282","author":"M Mazzali","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"pone.0234909.ref009","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jama.300.8.924","article-title":"Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial","volume":"300","author":"DI Feig","year":"2008","journal-title":"JAMA"},{"key":"pone.0234909.ref010","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","article-title":"Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"GBD 2016 Causes of Death Collaborators","year":"2017","journal-title":"Lancet"},{"key":"pone.0234909.ref011","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1445-5994.1991.tb01373.x","article-title":"Dubbo study of the elderly: sociological and cardiovascular risk factors at entry","volume":"21","author":"LA Simons","year":"1991","journal-title":"Aust N Z J Med"},{"key":"pone.0234909.ref012","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-2125.2010.03887.x","article-title":"Impact of allopurinol use on urate concentration and cardiovascular outcome","volume":"71","author":"L Wei","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"pone.0234909.ref013","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"M Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"pone.0234909.ref014","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12872-017-0513-6","article-title":"Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes","volume":"17","author":"JA Singh","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"pone.0234909.ref015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1377\/hlthaff.22.3.61","article-title":"Taiwan\u2019s new national health insurance program: genesis and experience so far","volume":"22","author":"TM Cheng","year":"2003","journal-title":"Health Aff"},{"key":"pone.0234909.ref016","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"RB D\u2019Agostino","year":"1998","journal-title":"Stat Med"},{"key":"pone.0234909.ref017","first-page":"1","article-title":"Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44\/42 MAPK and PDGFR \u03b2","volume":"12","author":"M K\u0131r\u00e7a","year":"2016","journal-title":"J Recept Signal Transduct Res"},{"key":"pone.0234909.ref018","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1743-7075-1-10","article-title":"Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle","volume":"1","author":"MR Hayden","year":"2004","journal-title":"Nutr Metab"},{"key":"pone.0234909.ref019","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2741\/3950","article-title":"Uric acid, hyperuricemia and vascular diseases","volume":"17","author":"M Jin","year":"2012","journal-title":"Front Biosci"},{"key":"pone.0234909.ref020","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/rheumatology\/keq037","article-title":"Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout","volume":"49","author":"E Krishnan","year":"2010","journal-title":"Rheumatology"},{"key":"pone.0234909.ref021","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/dom.13656","article-title":"Association between allopurinol and cardiovascular outcomes and all-cause mortality in diabetes: a retrospective, population-based cohort study","volume":"21","author":"A Weisman","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"pone.0234909.ref022","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","article-title":"Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy","volume":"40","author":"S Kojima","year":"2019","journal-title":"Eur Heart J"},{"key":"pone.0234909.ref023","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/01.CIR.85.6.2205","article-title":"Lipids and other risk factors selected by discriminant analysis in symptomatic patients with supra-aortic and peripheral atherosclerosis","volume":"85","author":"GB Vigna","year":"1992","journal-title":"Circulation"},{"key":"pone.0234909.ref024","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1755-5922.2008.00057.x","article-title":"Allopurinol treatment reduces arterial wave reflection in stroke survivors","volume":"26","author":"F Khan","year":"2008","journal-title":"Cardiovasc Ther"},{"key":"pone.0234909.ref025","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1161\/STROKEAHA.108.519793","article-title":"Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke: a randomized, double-blind, placebo-controlled trial","volume":"39","author":"SW Muir","year":"2008","journal-title":"Stroke"},{"key":"pone.0234909.ref026","first-page":"827","article-title":"Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context","volume":"335","author":"R Collins","year":"1990","journal-title":"Lancet"},{"key":"pone.0234909.ref027","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.atherosclerosis.2013.08.023","article-title":"Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies","volume":"231","author":"G Zhao","year":"2013","journal-title":"Atherosclerosis"},{"key":"pone.0234909.ref028","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/rheumatology\/kep069","article-title":"Allopurinol and mortality in hyperuricaemia patients","volume":"48","author":"AJ Luk","year":"2009","journal-title":"Rheumatology"},{"key":"pone.0234909.ref029","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/heart.87.3.229","article-title":"Effect of allopurinol on mortality and hospitalizations in chronic heart failure: a retrospective cohort study","volume":"87","author":"AD Struthers","year":"2002","journal-title":"Heart"},{"key":"pone.0234909.ref030","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(10)60391-1","article-title":"Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial","volume":"375","author":"A Noman","year":"2010","journal-title":"Lancet"},{"key":"pone.0234909.ref031","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1136\/heartjnl-2014-306670","article-title":"Allopurinol use and risk of non-fatal acute myocardial infarction","volume":"101","author":"FJ de Abajo","year":"2015","journal-title":"Heart"},{"key":"pone.0234909.ref032","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/annrheumdis-2012-202972","article-title":"Impact of allopurinol on risk of myocardial infarction","volume":"74","author":"L Grimaldi-Bensouda","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"pone.0234909.ref033","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ijcard.2006.05.003","article-title":"Uric acid in CHF: marker or player in a metabolic disease?","volume":"115","author":"W Doehner","year":"2007","journal-title":"Int J Cardiol"},{"key":"pone.0234909.ref034","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/hrt.2004.057190","article-title":"Xanthine oxidase inhibition for chronic heart failure: Is allopurinol the next therapeutic advance in heart failure?","volume":"91","author":"W Doehner","year":"2005","journal-title":"Heart"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0234909","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T03:33:23Z","timestamp":1723088003000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0234909"}},"subtitle":[],"editor":[{"given":"Hans-Peter","family":"Brunner-La Rocca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0234909","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]}}}